Hemostasis

HEMOSONICS AWARDED FDA 510(k) CLEARANCE FOR QUANTRA® HEMOSTASIS SYSTEM WITH QSTAT® CARTRIDGE

Retrieved on: 
Wednesday, November 30, 2022
Barts Health NHS Trust, Patient, Trauma, Public health, Food, Headquarters, R, PBM, Royal London, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, System, Thrombosis, Paola Lattus, Senior lecturer, Trust, SEER, Blood, Hemostasis, High-dependency unit, St Bartholomew's Hospital, FDA, Medical imaging, Medical device, Hospital

DURHAM, N.C., Nov. 30, 2022 /PRNewswire/ -- HemoSonics, LLC, a leading medical device company delivering individualized diagnostic solutions for Patient Blood Management (PBM), announced today that it has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for the Quantra Hemostasis System with QStat Cartridge.

Key Points: 
  • "The Quantra Hemostasis System with QStat Cartridge is breaking new ground and leading innovation in the point-of-care and laboratory-based whole blood hemostasis testing market.
  • The FDA clearance of the QStat Cartridge expands the Quantra System's indications for use to include trauma, and liver transplantation procedures.
  • "The Quantra Hemostasis System with QStat and QPlus Cartridges will assist more clinicians in determining which specific blood products are needed to rapidly treat individual patients.
  • HemoSonics is part of the Stago group, a leading company in thein vitrodiagnostics industry dedicated to exploring thrombosis and hemostasis.

Merit Medical Launches the PreludeSYNC EZ™ Radial Compression Device

Retrieved on: 
Monday, November 21, 2022
Endoscopy, Heart, Bleeding, Femoral artery, MMSI, Blood, Wrist, Hospital, PCI, Radiology, EZ, Critical care, Percutaneous coronary intervention, Cardiology, Radial artery, Hemostasis, Radial, Medical imaging

SOUTH JORDAN, Utah, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of the PreludeSYNC EZ Radial Compression Device.

Key Points: 
  • SOUTH JORDAN, Utah, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of the PreludeSYNC EZ Radial Compression Device.
  • Created with the patient and clinician in mind, the PreludeSYNC EZ provides a simplified alternative to the two-strap compression band currently on the market.
  • 3 Benefits include fewer bleeding complications, improved patient comfort, and decreased procedure costs compared to femoral procedures, or those performed through the femoral artery in the groin.3
    Learn more about the PreludeSYNC EZ Radial Compression Device.
  • Merit Medical is fully invested in being a leader in radial artery access, said Fred P. Lampropoulos, Merit Medicals Chairman and CEO.

Global Hemostasis Diagnostics Market to Reach $2.7 Billion by 2027 with a 4.8% CAGR - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022
Medical Devices, Other Health, Health, Health Technology, Medical Supplies, D-dimer, Growth, COVID-19, Hemostasis, Pet

In the changed post COVID-19 business landscape, the global market for Hemostasis Diagnostics estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$2.7 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027.

Key Points: 
  • In the changed post COVID-19 business landscape, the global market for Hemostasis Diagnostics estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$2.7 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027.
  • Prothrombin Test Time (PT), one of the segments analyzed in the report, is projected to record a 4.5% CAGR and reach US$1.1 Billion by the end of the analysis period.
  • China, the world's second largest economy, is forecast to reach a projected market size of US$561.5 Million by the year 2027 trailing a CAGR of 8.5% over the analysis period 2020 to 2027.
  • In the global Fibrinogen segment, USA, Canada, Japan, China and Europe will drive the 4.9% CAGR estimated for this segment.

UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors

Retrieved on: 
Wednesday, November 9, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Marketing, Strategic planning, Hemostasis, Nasdaq, St. Lawrence University, Technology, Board, Solution, Board of directors, Johnson & Johnson, Company, Neoplasm, Patient, Mitomycins, Surgeon, Worldwide, Boston Scientific, Economics, Fine chemical, Pharmaceutical industry, Management, Medicine, Maggot therapy, Ethicon Inc.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the appointment of Dan Wildman to its Board of Directors, effective immediately.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the appointment of Dan Wildman to its Board of Directors, effective immediately.
  • Dan Wildman, Chairman of the Board of Progenerative Medical, Inc., a 40-year veteran of the medical device industry, and Strategic Advisor to several medical device and pharmaceutical companies, has agreed to join UroGens board, effective immediately.
  • We are pleased to welcome Dan Wildman to UroGens Board of Directors, said Liz Barrett, President and Chief Executive Officer, UroGen.
  • I am impressed with UroGens innovative technology and its potential to disrupt other areas of urologic oncology, said Dan Wildman.

$161+ Billion Worldwide In-Vitro Diagnostics Industry to 2031 - North America was the Largest Region in 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 2, 2022
Other Science, Science, IOT, Human body, Tissue, IVD, Efficiency, Organization, WIFI, Blood, Hospital, Hematology, Microbiology, Asia-Pacific, Point-of-care testing, Hemostasis, Patient, Enzyme, Medical device

In-vitro diagnostics are tests performed on samples collected from the human body such as tissues and blood.

Key Points: 
  • In-vitro diagnostics are tests performed on samples collected from the human body such as tissues and blood.
  • The main types of in-vitro diagnostics equipment are point-of-care diagnostics devices and equipment, immunochemistry diagnostic devices and equipment, clinical chemistry diagnostics devices and equipment, molecular diagnostics devices and equipment, microbiology diagnostic devices and equipment, hemostasis diagnostic devices and equipment, hematology diagnostic devices, and equipment, and immunohematology diagnostic devices, and equipment.
  • North America was the largest region in the global in-vitro diagnostics market in 2021.
  • The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Global Hemostasis Products Market Business Report 2022: Market to Reach $7.5 Billion by 2027 - Increasing Surgical Volumes and Trauma Cases Drives Market Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 1, 2022
Health, Other Health, Growth, COVID-19, CAGR, Hemostasis, Pet

The "Hemostasis Products: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hemostasis Products: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • Topical Hemostasis, one of the segments analyzed in the report, is projected to record a 3.4% CAGR and reach US$2.2 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 5.5% CAGR
    The Hemostasis Products market in the U.S. is estimated at US$1.6 Billion in the year 2020.
  • In the global Advanced Hemostasis segment, USA, Canada, Japan, China and Europe will drive the 3.3% CAGR estimated for this segment.

FTC Approves Final Order Protecting Patients Who Rely on Medical Instruments Used in Sinus Procedures

Retrieved on: 
Monday, October 31, 2022
Commission, ENT, Social media, Federal Trade Commission, Intersection, Acquisition, Blog, Ear, Complaint, Medtronic, News, Nose, FTC, LLC, Hemostasis

Under the terms of the final settlement, Medtronic must divest Intersect subsidiary Fiagon which makes ear, nose, and throat navigation systems and balloon sinus dilation products to Hemostasis, LLC.

Key Points: 
  • Under the terms of the final settlement, Medtronic must divest Intersect subsidiary Fiagon which makes ear, nose, and throat navigation systems and balloon sinus dilation products to Hemostasis, LLC.
  • First announced in May 2022, the complaint alleged that markets for ear, nose, and throat navigation systems and balloon sinus dilation products are already concentrated.
  • The divestiture will prevent further concentration that would ultimately harm consumers, according to the FTC.
  • For the latest news and resources, follow the FTC on social media, subscribe to press releases and read our blog.

$32.2 Billion Global Interventional Cardiology Devices Market Report to 2027: Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, October 28, 2022
Medical Devices, Health, CAD, Diabetes, OCT, Plaque, Degenerative disease, TMR, Prevalence, Growth, Arrhythmia, Catheter, Hemostasis, Angioplasty, Atherectomy, Stent, COVID-19, CABG, Coronary artery disease, FFR, MI, IVUS, Hypertension, Solution, Pharmaceutical industry, Medical imaging

Interventional cardiology devices refer to the medical equipment and guiding tools used for performing cardiovascular procedures, such as angioplasty and stenting.

Key Points: 
  • Interventional cardiology devices refer to the medical equipment and guiding tools used for performing cardiovascular procedures, such as angioplasty and stenting.
  • Some of the commonly used devices include angioplasty balloons, stents, mitral, pulmonary and tricuspid valves, catheters, plaque modification and hemodynamic flow alteration devices.
  • Interventional cardiology and embolic protection devices are widely used to capture embolic debris to ensure continuous blood flow and preventing blockages.
  • The publisher provides an analysis of the key trends in each sub-segment of the global interventional cardiology devices market, along with forecasts at the global, regional and country level from 2022-2027.

Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Fall

Retrieved on: 
Tuesday, October 18, 2022
News, Method, Securities Act of 1933, SEC, Therapy, Biotechnology, Patient, AC5, Hemostasis, CEO, Trauma, Securities Exchange Act of 1934, Risk, MD

Arch Therapeutics, Inc. is a biotechnology company with a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma, and interventional care.

Key Points: 
  • Arch Therapeutics, Inc. is a biotechnology company with a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma, and interventional care.
  • Arch is developing wound care and biosurgical products based on an innovative self-assembling peptide technology platform with the goal of improving healing outcomes for patients.
  • Arch has received regulatory clearance to market AC5 Advanced Wound System in the United States and AC5 Topical Hemostat in Europe.
  • 2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.

HEMOSONICS APPOINTS DR. BRUCE SPIESS AS MEDICAL DIRECTOR AND EXHIBITS DIAGNOSTIC SOLUTIONS AT ANESTHESIOLOGY®, THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS (ASA) ANNUAL MEETING

Retrieved on: 
Friday, October 21, 2022
Quanta, Rush University, Time, Communication, Bleeding, Blood, Board of High School and Intermediate Education Uttar Pradesh, American Board of Commissioners for Foreign Missions, LLC, LIS, Society, SEER, Patient, Thrombosis, ASA, Publication, Elasticity, Cardiac surgery, National Board of Medical Examiners, Ernest, R, Medical director, FAHA, Industry, Convention, PBM, Hemostasis, Critical, Center Stage, Health, American Heart Association, Mayo Clinic Graduate School of Biomedical Sciences, Medicine, EMR, Spiess, American Society of Anesthesiologists, Headquarters, American Board of Anesthesiology, National Primate Research Exhibition Hall, Solution, Medical device, Anesthesiology, MD

HemoSonics is also pleased to announce that Bruce Spiess, MD, FAHA, has joined the company as Medical Director.

Key Points: 
  • HemoSonics is also pleased to announce that Bruce Spiess, MD, FAHA, has joined the company as Medical Director.
  • With over 40 years of medical experience, Dr. Spiess had an exemplary career as a clinician educator as well as a globally recognized researcher.
  • Dr. Spiess is also a Diplomate of the American Board of Anesthesiology, and the National Board of Medical Examiners, and a Fellow of the American Heart Association.
  • HemoSonics is part of the Stago group, a leading company in thein vitrodiagnostics industry dedicated to exploring thrombosis and hemostasis.